Clinical Trials Logo

Prolonged Air Leak clinical trials

View clinical trials related to Prolonged Air Leak.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04065880 Completed - Prolonged Air Leak Clinical Trials

Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation

Start date: April 1, 2020
Phase: N/A
Study type: Interventional

Postoperative prolonged air leak (PAL), referring to the passage of air from the lung parenchyma into the pleural space, is one of the most frequent postoperative complications after lung resection. To control air leak, there are two different products certified since years: TachoSil® and Neoveil®. This study is to investigate the difference of TachoSil® and Neoveil® in patients with PAL.

NCT ID: NCT02491671 Completed - Lung Resection Clinical Trials

Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection

Start date: November 24, 2015
Phase: Phase 3
Study type: Interventional

The effectiveness of tissue sealants to prevent Prolonged Air Leak (PAL) after lung resection procedures remains unproved. The investigators hypothesize that one of the main reasons for that is the heterogeneity of previously studied populations. Since currently the risk of postoperative PAL can be scored with a reasonable accuracy, the aim of this research is to investigate the effect of routine application of a novel tissue sealant in patients selected on the basis of a high risk of PAL estimated before surgery.

NCT ID: NCT01166516 Completed - Prolonged Air Leak Clinical Trials

IBV Valve System for the Treatment of Prolonged Air Leak Under HDE H060002 - Post Approval Study

HUD-PAS
Start date: April 2010
Phase: N/A
Study type: Interventional

Study to collect post-market safety data for HUD IBV Valve System, a device to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged air leaks following lobectomy, segmentectomy, or LVRS. An air leak present on post-operative day 7 is considered prolonged unless present only during forced exhalation or cough. An air leak present on day 5 should be considered for treatment if it is: 1)continuous, 2) present during normal inhalation phase of inspiration, or 3) present upon normal expiration and accompanied by subcutaneous emphysema or respiratory compromise.